EP 3974027 A4 20230816 - STABILIZED PACAP PEPTIDE
Title (en)
STABILIZED PACAP PEPTIDE
Title (de)
STABILISIERTES PACAP-PEPTID
Title (fr)
PEPTIDE PACAP STABILISÉ
Publication
Application
Priority
- JP 2019091696 A 20190514
- JP 2020019344 W 20200514
Abstract (en)
[origin: EP3974027A1] The purpose of the present invention is to provide a PACAP peptide having improved stability. The present invention is based on the finding that the stability of PACAP is significantly improved by substituting aspartic acid at positions 3 and 8 in the sequence of PACAP with at least one amino acid selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (50xa).
IPC 8 full level
C07K 14/575 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61P 9/00 (2018.01); A61P 25/00 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01); C07K 14/575 (2013.01); A61K 38/00 (2013.01)
Citation (search report)
- [I] EP 1752158 A1 20070214 - SENJU PHARMA CO [JP], et al
- [I] DOAN NGOC-DUC ET AL: "Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects", BIOCHEMICAL PHARMACOLOGY, vol. 81, no. 4, 27 November 2010 (2010-11-27), US, pages 552 - 561, XP093059058, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2010.11.015
- See also references of WO 2020230867A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 3974027 A1 20220330; EP 3974027 A4 20230816; CN 113853236 A 20211228; JP WO2020230867 A1 20201119; WO 2020230867 A1 20201119
DOCDB simple family (application)
EP 20805414 A 20200514; CN 202080035518 A 20200514; JP 2020019344 W 20200514; JP 2021519490 A 20200514